Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, …
Today’s healthcare sector offered a great deal of rumble and tumble with the following volatile stocks making headlines today: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), …
Ariad Pharmaceuticals, Inc. Investors in Ariad Pharmaceuticals, Inc.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) under …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) recently presented updated data from the pivotal ALTA trial of brigatinib in refractory ALK+ non–small-cell lung cancer (NSCLC) was …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in ALK-positive …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the results of clinical and translational studies on Iclusig®(ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the ongoing Phase 1/2 and pivotal …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released yesterday morning the FDA’s decision approving the firm’s pipeline drug Iclusig (ponatinib), used in the treatment of chronic …
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the U.
